High-affinity target binding engineered via fusion of a single-domain antibody fragment with a ligand-tailored SH3 domain

PLoS ONE

Volumn 7, Issue 7, 2012, Pages

  Järviluoma, Annika ^a   Strandin, Tomas ^a   Lülf, Sebastian ^b   Bouchet, Jérôme ^c   Mäkelä, Anna R ^d   Geyer, Matthias ^b   Benichou, Serge ^c   Saksela, Kalle ^a,e  

^a UNIVERSITY OF HELSINKI   (Finland)

^b MAX PLANCK INSTITUTE OF MOLECULAR PHYSIOLOGY   (Germany)

^c INSTITUT COCHIN   (France)

^d NEXT Biomed Technologies NBT Oy   (Finland)

^e HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

BINDING PROTEIN; HYBRID PROTEIN; NEF PROTEIN; NEFFIN PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; EMBRYO; ESCHERICHIA COLI; HUMAN; HUMAN CELL; LIGAND BINDING; MOLECULAR RECOGNITION; NONHUMAN; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; PROTEIN SYNTHESIS; PROTEIN TARGETING;

ANTI-HIV AGENTS; ESCHERICHIA COLI; HEK293 CELLS; HUMANS; KINETICS; NEF GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; PROTEIN BINDING; PROTO-ONCOGENE PROTEINS C-HCK; RECOMBINANT FUSION PROTEINS; SINGLE-DOMAIN ANTIBODIES; SRC HOMOLOGY DOMAINS;

BACTERIA (MICROORGANISMS); HUMAN IMMUNODEFICIENCY VIRUS 1; LAMA (MAMMAL);

EID: 84863617815     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0040331     Document Type: Article

References (48)

1. Kohler G, Milstein C, (1975) Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256: 495-497.
2. Nelson AL, Dhimolea E, Reichert JM, (2010) Development trends for human monoclonal antibody therapeutics. Nat Rev Drug Discov 9: 767-774.
3. Scolnik PA, (2009) mAbs: a business perspective. MAbs 1: 179-184.
4. Holliger P, Hudson PJ, (2005) Engineered antibody fragments and the rise of single domains. Nat Biotechnol 23: 1126-1136.
5. Pluckthun A, Pack P, (1997) New protein engineering approaches to multivalent and bispecific antibody fragments. Immunotechnology 3: 83-105.
6. Foote J, Eisen HN, (1995) Kinetic and affinity limits on antibodies produced during immune responses. Proc Natl Acad Sci U S A 92: 1254-1256.
7. Foote J, Eisen HN, (2000) Breaking the affinity ceiling for antibodies and T cell receptors. Proc Natl Acad Sci U S A 97: 10679-10681.
8. Boder ET, Midelfort KS, Wittrup KD, (2000) Directed evolution of antibody fragments with monovalent femtomolar antigen-binding affinity. Proc Natl Acad Sci U S A 97: 10701-10705.
9. Demarest SJ, Glaser SM, (2008) Antibody therapeutics, antibody engineering, and the merits of protein stability. Curr Opin Drug Discov Devel 11: 675-687.
10. Ewert S, Huber T, Honegger A, Pluckthun A, (2003) Biophysical properties of human antibody variable domains. J Mol Biol 325: 531-553.
11. Honegger A, (2008) Engineering antibodies for stability and efficient folding. Handb Exp Pharmacol pp. 47-68.
12. Martineau P, Betton JM, (1999) In vitro folding and thermodynamic stability of an antibody fragment selected in vivo for high expression levels in Escherichia coli cytoplasm. J Mol Biol 292: 921-929.
13. Binz HK, Amstutz P, Pluckthun A, (2005) Engineering novel binding proteins from nonimmunoglobulin domains. Nat Biotechnol 23: 1257-1268.
14. Gebauer M, Skerra A, (2009) Engineered protein scaffolds as next-generation antibody therapeutics. Curr Opin Chem Biol 13: 245-255.
15. Hey T, Fiedler E, Rudolph R, Fiedler M, (2005) Artificial, non-antibody binding proteins for pharmaceutical and industrial applications. Trends Biotechnol 23: 514-522.
16. Nygren PA, (2008) Alternative binding proteins: affibody binding proteins developed from a small three-helix bundle scaffold. FEBS J 275: 2668-2676.
17. Koide A, Koide S, (2007) Monobodies: antibody mimics based on the scaffold of the fibronectin type III domain. Methods Mol Biol 352: 95-109.
18. Stumpp MT, Binz HK, Amstutz P, (2008) DARPins: a new generation of protein therapeutics. Drug Discov Today 13: 695-701.
19. Gmeiner WH, Horita DA, (2001) Implications of SH3 domain structure and dynamics for protein regulation and drug design. Cell Biochem Biophys 35: 127-140.
20. Kaneko T, Li L, Li SS, (2008) The SH3 domain-a family of versatile peptide- and protein-recognition module. Front Biosci 13: 4938-4952.
21. Grabulovski D, Kaspar M, Neri D, (2007) A novel, non-immunogenic Fyn SH3-derived binding protein with tumor vascular targeting properties. J Biol Chem 282: 3196-3204.
22. Hiipakka M, Poikonen K, Saksela K, (1999) SH3 domains with high affinity and engineered ligand specificities targeted to HIV-1 Nef. J Mol Biol 293: 1097-1106.
23. Hiipakka M, Saksela K, (2007) Versatile retargeting of SH3 domain binding by modification of non-conserved loop residues. FEBS Lett 581: 1735-1741.
24. Ward ES, Gussow D, Griffiths AD, Jones PT, Winter G, (1989) Binding activities of a repertoire of single immunoglobulin variable domains secreted from Escherichia coli. Nature 341: 544-546.
25. Muyldermans S, (2001) Single domain camel antibodies: current status. J Biotechnol 74: 277-302.
26. Holt LJ, Herring C, Jespers LS, Woolven BP, Tomlinson IM, (2003) Domain antibodies: proteins for therapy. Trends Biotechnol 21: 484-490.
27. Verheesen P, ten Haaft MR, Lindner N, Verrips CT, de Haard JJ, (2003) Beneficial properties of single-domain antibody fragments for application in immunoaffinity purification and immuno-perfusion chromatography. Biochim Biophys Acta 1624: 21-28.
28. Wesolowski J, Alzogaray V, Reyelt J, Unger M, Juarez K, et al. (2009) Single domain antibodies: promising experimental and therapeutic tools in infection and immunity. Med Microbiol Immunol 198: 157-174.
29. Huang L, Muyldermans S, Saerens D, (2010) Nanobodies®: proficient tools in diagnostics. Expert Rev Mol Diagn 10: 777-785.
30. Neri D, Momo M, Prospero T, Winter G, (1995) High-affinity antigen binding by chelating recombinant antibodies (CRAbs). J Mol Biol 246: 367-373.
31. Lim WA, (2010) Designing customized cell signalling circuits. Nat Rev Mol Cell Biol 11: 393-403.
32. Pawson T, Nash P, (2003) Assembly of cell regulatory systems through protein interaction domains. Science 300: 445-452.
33. Huang J, Koide A, Makabe K, Koide S, (2008) Design of protein function leaps by directed domain interface evolution. Proc Natl Acad Sci U S A 105: 6578-6583.
34. Silverman J, Liu Q, Bakker A, To W, Duguay A, et al. (2005) Multivalent avimer proteins evolved by exon shuffling of a family of human receptor domains. Nat Biotechnol 23: 1556-1561.
35. Bouchet J, Basmaciogullari SE, Chrobak P, Stolp B, Bouchard N, et al. (2011) Inhibition of the Nef regulatory protein of HIV-1 by a single-domain antibody. Blood.
36. Hiipakka M, Huotari P, Manninen A, Renkema GH, Saksela K, (2001) Inhibition of cellular functions of HIV-1 Nef by artificial SH3 domains. Virology 286: 152-159.
37. Breuer S, Schievink SI, Schulte A, Blankenfeldt W, Fackler OT, et al. (2011) Molecular design, functional characterization and structural basis of a protein inhibitor against the HIV-1 pathogenicity factor Nef. PloS one 6: e20033.
38. Horenkamp FA, Breuer S, Schulte A, Lulf S, Weyand M, et al. (2011) Conformation of the dileucine-based sorting motif in HIV-1 Nef revealed by intermolecular domain assembly. Traffic 12: 867-877.
39. Drake AW, Myszka DG, Klakamp SL, (2004) Characterizing high-affinity antigen/antibody complexes by kinetic- and equilibrium-based methods. Anal Biochem 328: 35-43.
40. Nieba L, Krebber A, Pluckthun A, (1996) Competition BIAcore for measuring true affinities: large differences from values determined from binding kinetics. Analytical biochemistry 234: 155-165.
41. Schuck P, Zhao H, (2010) The role of mass transport limitation and surface heterogeneity in the biophysical characterization of macromolecular binding processes by SPR biosensing. Methods Mol Biol 627: 15-54.
42. Moarefi I, LaFevre-Bernt M, Sicheri F, Huse M, Lee CH, et al. (1997) Activation of the Src-family tyrosine kinase Hck by SH3 domain displacement. Nature 385: 650-653.
43. Muyldermans S, Baral TN, Retamozzo VC, De Baetselier P, De Genst E, et al. (2009) Camelid immunoglobulins and nanobody technology. Veterinary immunology and immunopathology 128: 178-183.
44. Saerens D, Ghassabeh GH, Muyldermans S, (2008) Single-domain antibodies as building blocks for novel therapeutics. Curr Opin Pharmacol 8: 600-608.
45. Hiipakka M, Saksela K, (2002) Capacity of simian immunodeficiency virus strain mac Nef for high-affinity Src homology 3 (SH3) binding revealed by ligand-tailored SH3 domains. The Journal of general virology 83: 3147-3152.
46. Manninen A, Hiipakka M, Vihinen M, Lu W, Mayer BJ, et al. (1998) SH3-Domain binding function of HIV-1 Nef is required for association with a PAK-related kinase. Virology 250: 273-282.
47. Haller C, Rauch S, Michel N, Hannemann S, Lehmann MJ, et al. (2006) The HIV-1 pathogenicity factor Nef interferes with maturation of stimulatory T-lymphocyte contacts by modulation of N-Wasp activity. J Biol Chem 281: 19618-19630.
48. Neri D, Montigiani S, Kirkham PM, (1996) Biophysical methods for the determination of antibody-antigen affinities. Trends Biotechnol 14: 465-470.